CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing
Purpose Accurate glioma classification affects patient management and is challenging on non- or low-enhancing gliomas. This study investigated the clinical value of different chemical exchange saturation transfer (CEST) metrics for glioma classification and assessed the diagnostic effect of the presence of abundant fluid in glioma subpopulations. Methods Forty-five treatment-naïve glioma patients with known isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status received CEST MRI (B1rms = 2μT, Tsat = 3.5 s) at 3 T. Magnetization transfer ratio asymmetry and CEST metrics (amides: offset range 3–4 ppm, amines: 1.5–2.5 ppm, amide/amine ratio) were calculated with two models: ‘asymmetry-based’ (AB) and ‘fluid-suppressed’ (FS). The presence of T2/FLAIR mismatch was noted. Results IDH-wild type had higher amide/amine ratio than IDH-mutant_1p/$ 19q^{codel} $ (p < 0.022). Amide/amine ratio and amine levels differentiated IDH-wild type from IDH-mutant (p < 0.0045) and from IDH-mutant_1p/$ 19q^{ret} $ (p < 0.021). IDH-mutant_1p/$ 19q^{ret} $ had higher amides and amines than IDH-mutant_1p/$ 19q^{codel} $ (p < 0.035). IDH-mutant_1p/$ 19q^{ret} $ with AB/FS mismatch had higher amines than IDH-mutant_1p/$ 19q^{ret} $ without AB/FS mismatch ( < 0.016). In IDH-mutant_1p/$ 19q^{ret} $, the presence of AB/FS mismatch was closely related to the presence of T2/FLAIR mismatch (p = 0.014). Conclusions CEST-derived biomarkers for amides, amines, and their ratio can help with histomolecular staging in gliomas without intense contrast enhancement. T2/FLAIR mismatch is reflected in the presence of AB/FS CEST mismatch. The AB/FS CEST mismatch identifies glioma subgroups that may have prognostic and clinical relevance..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine & molecular imaging - 49(2022), 7 vom: 14. Jan., Seite 2377-2391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mancini, Laura [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
1p/19q codeletion |
|---|
| Anmerkungen: |
© The Author(s) 2022. corrected publication 2022 |
|---|
| doi: |
10.1007/s00259-022-05676-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078760285 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078760285 | ||
| 003 | DE-627 | ||
| 005 | 20230514123205.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-022-05676-1 |2 doi | |
| 035 | |a (DE-627)OLC2078760285 | ||
| 035 | |a (DE-He213)s00259-022-05676-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Mancini, Laura |e verfasserin |0 (orcid)0000-0002-4596-3551 |4 aut | |
| 245 | 1 | 0 | |a CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022. corrected publication 2022 | ||
| 520 | |a Purpose Accurate glioma classification affects patient management and is challenging on non- or low-enhancing gliomas. This study investigated the clinical value of different chemical exchange saturation transfer (CEST) metrics for glioma classification and assessed the diagnostic effect of the presence of abundant fluid in glioma subpopulations. Methods Forty-five treatment-naïve glioma patients with known isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status received CEST MRI (B1rms = 2μT, Tsat = 3.5 s) at 3 T. Magnetization transfer ratio asymmetry and CEST metrics (amides: offset range 3–4 ppm, amines: 1.5–2.5 ppm, amide/amine ratio) were calculated with two models: ‘asymmetry-based’ (AB) and ‘fluid-suppressed’ (FS). The presence of T2/FLAIR mismatch was noted. Results IDH-wild type had higher amide/amine ratio than IDH-mutant_1p/$ 19q^{codel} $ (p < 0.022). Amide/amine ratio and amine levels differentiated IDH-wild type from IDH-mutant (p < 0.0045) and from IDH-mutant_1p/$ 19q^{ret} $ (p < 0.021). IDH-mutant_1p/$ 19q^{ret} $ had higher amides and amines than IDH-mutant_1p/$ 19q^{codel} $ (p < 0.035). IDH-mutant_1p/$ 19q^{ret} $ with AB/FS mismatch had higher amines than IDH-mutant_1p/$ 19q^{ret} $ without AB/FS mismatch ( < 0.016). In IDH-mutant_1p/$ 19q^{ret} $, the presence of AB/FS mismatch was closely related to the presence of T2/FLAIR mismatch (p = 0.014). Conclusions CEST-derived biomarkers for amides, amines, and their ratio can help with histomolecular staging in gliomas without intense contrast enhancement. T2/FLAIR mismatch is reflected in the presence of AB/FS CEST mismatch. The AB/FS CEST mismatch identifies glioma subgroups that may have prognostic and clinical relevance. | ||
| 650 | 4 | |a Isocitrate dehydrogenase | |
| 650 | 4 | |a 1p/19q codeletion | |
| 650 | 4 | |a Oligodendroglioma | |
| 650 | 4 | |a Chemical exchange saturation transfer | |
| 650 | 4 | |a Glioma risk stratification | |
| 700 | 1 | |a Casagranda, Stefano |4 aut | |
| 700 | 1 | |a Gautier, Guillaume |4 aut | |
| 700 | 1 | |a Peter, Philippe |4 aut | |
| 700 | 1 | |a Lopez, Bruno |4 aut | |
| 700 | 1 | |a Thorne, Lewis |4 aut | |
| 700 | 1 | |a McEvoy, Andrew |4 aut | |
| 700 | 1 | |a Miserocchi, Anna |4 aut | |
| 700 | 1 | |a Samandouras, George |4 aut | |
| 700 | 1 | |a Kitchen, Neil |4 aut | |
| 700 | 1 | |a Brandner, Sebastian |4 aut | |
| 700 | 1 | |a De Vita, Enrico |4 aut | |
| 700 | 1 | |a Torrealdea, Francisco |4 aut | |
| 700 | 1 | |a Rega, Marilena |4 aut | |
| 700 | 1 | |a Schmitt, Benjamin |4 aut | |
| 700 | 1 | |a Liebig, Patrick |4 aut | |
| 700 | 1 | |a Sanverdi, Eser |4 aut | |
| 700 | 1 | |a Golay, Xavier |4 aut | |
| 700 | 1 | |a Bisdas, Sotirios |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine & molecular imaging |d Springer Berlin Heidelberg, 1976 |g 49(2022), 7 vom: 14. Jan., Seite 2377-2391 |w (DE-627)129097969 |w (DE-600)8236-3 |w (DE-576)014434644 |x 0340-6997 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:7 |g day:14 |g month:01 |g pages:2377-2391 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00259-022-05676-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 7 |b 14 |c 01 |h 2377-2391 | ||